Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹1,935.50
3.20 (0.17%)
Medium VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹4.64L Cr
LARGE CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
40.2
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹1,548+25.0%
52W High₹1,953.9-0.9%
Current Price
₹1,935.50
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹1,548.40
Upper Circuit₹2,322.60
Reference Price
₹1,935.50
Investment Checklist
Triple Bottom on 1W (BREAKOUT CONFIRMED) — target ₹2141.8
Inverse Head and Shoulders on 1W (BREAKOUT CONFIRMED) — target ₹2141.8
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
Composite score 43.69 (BUY) with 81.6% confidence
SuperTrend(10,3): Price above SuperTrend (Industry Standard (Swing/Medium-Term))
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
82%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
1875.45
EMA50
1836.16
EMA200
1755.46
Price Action
MIXED
NEUTRAL
Higher Highs5
Higher Lows7
Lower Highs4
Lower Lows2
Support & Resistance Levels
Resistance (Above)
No recent resistance detected
Support (Below)
₹1909.50
₹1846.00
₹1814.87
₹1705.04
₹1614.53
Volume Analysis
TrendINCREASING
Change+13.60%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹1916.14
3% Risk₹1877.43
5% Risk₹1838.72
7% Risk (Custom)
₹1800.01Technical Levels
1x ATR (Volatility)₹1901.66
2x ATR (Swing)₹1867.82
3x ATR (Trend)₹1833.98
Immediate Support₹1909.50
Moving Averages
EMA 9 (Short-term)₹1902.75
EMA 20 (Medium-term)₹1875.45
EMA 50 (Trend)₹1836.16
EMA 200 (Long-term)₹1755.46
Financials
Financial Analysis
| Metric | Dec '24 | Mar '25 | Jun '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹13,436.9 Cr | ₹12,815.6 Cr | ₹13,786.1 Cr | ₹15,469.1 Cr |
| Net Profit | ₹2,903.4 Cr | ₹2,149.9 Cr | ₹2,278.6 Cr | ₹3,368.8 Cr |
| EPS | ₹12.10 | — | ₹9.50 | ₹14.00 |
| Operating Profit | ₹4,158.5 Cr | ₹3,967.3 Cr | ₹3,948.1 Cr | ₹5,037.9 Cr |
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Biocon Limited | ₹418.50 | +3.70% | 177.4 | ₹67.83K Cr mid Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 07 Jul 2026 | Dividend - Rs 5 Per Share | DIVIDEND |
| 05 Feb 2026 | Interim Dividend - Rs 11 Per Share | INTERIM_DIVIDEND |
| 07 Jul 2025 | Dividend - Rs 5.50 Per Share | DIVIDEND |
| 06 Feb 2025 | Interim Dividend - Rs 10.50 Per Share | INTERIM_DIVIDEND |
| 12 Jul 2024 | Dividend - Rs 5 Per Share | DIVIDEND |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
| Date | Purpose | Type |
|---|---|---|
| 31 Jul 2026 | Financial Results | RESULTS |
Latest News
News for SUNPHARMA
View All
positive
ET Markets - Stocks 1d ago
Sun Pharma among 4 stocks to hit 52-week highs & rally up to 25% in a month
The Sensex ended higher as select BSE 200 stocks touched fresh 52-week highs. FSN E-Commerce Ventures, Titan, Sun Pharmaceutical Industries and Lenskart Solutions led the momentum.
ABSL10BANKBSEBSLSENETFGEQUAL200ESENSEXHDFCSENSEXLENSKARTMIDSELIETFMOIPOMOM30IETFMOMENTUMMOMENTUM30MOMOMENTUMNEXT30ADDNIFTYQLITYNYKAASELECTIPOSENSEXADDSENSEXAXISSENSEXBETASENSEXETFSENSEXIETFSNXT30BEESSNXT50BETASPARCSUNPHARMATITANConsumer DurablesConsumer Services
NEWS
positive
Business Standard - Markets 4d ago
Sun Pharmaceutical Industries Ltd spurts 0.07%, up for five straight sessions
Sun Pharmaceutical Industries Ltd is quoting at Rs 1914.2, up 0.07% on the day as on 12:44 IST on the NSE. The stock is up 14.45% in last one year as compared to a 4.11% fall in NIFTY and a 16.43% fall in the Nifty Pharma.
ABSLBANETFABSLNN50ETABSLPSEAONELIQUIDAONENIFTYAONETMMQ50AONETOTALBSLNIFTYGSEC10ABSLHEALTHYMOMENTUMNIFTYQLITYPHARMABEESSPARCSUNPHARMATECHFinancial ServicesHealthcare
positive
CNBC TV18 - Markets 17d ago
Indian pharma, CDMOs set to gain from US cancer drug supply crunch: Bernstein
Zydus Lifesciences, Lupin and Sun Pharmaceutical Industries could benefit from a US oncology drug supply crunch and India's emerging GLP-1 market opportunity, according to Nandan Kulkarni, Senior Analyst-India Healthcare at Bernstein. He believes Indian biopharma companies are strengthening their role in global healthcare supply chains.
GLOBALHCGHCG-REHEALTHCAREHEALTHYLUPINSPARCSUNPHARMAZYDUSLIFEConsumer ServicesFinancial Services